Format
Sort by

Send to

Choose Destination

Search results

Items: 17

1.

Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer.

Sarduy MR, García I, Coca MA, Perera A, Torres LA, Valenzuela CM, Baladrón I, Solares M, Reyes V, Hernández I, Perera Y, Martínez YM, Molina L, González YM, Ancízar JA, Prats A, González L, Casacó CA, Acevedo BE, López-Saura PA, Alonso DF, Gómez R, Perea-Rodríguez SE; CERVIFARM-300-II Study Group.

Br J Cancer. 2015 May 12;112(10):1636-43. doi: 10.1038/bjc.2015.137. Epub 2015 Apr 16.

2.

Recombinant streptokinase vs phenylephrine-based suppositories in acute hemorrhoids, randomized, controlled trial (THERESA-3).

Hernández-Bernal F, Castellanos-Sierra G, Valenzuela-Silva CM, Catasús-Álvarez KM, Valle-Cabrera R, Aguilera-Barreto A, López-Saura PA; THERESA-3 Group of Investigators.

World J Gastroenterol. 2014 Feb 14;20(6):1594-601. doi: 10.3748/wjg.v20.i6.1594.

3.

Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers.

Yera-Alos IB, Alonso-Carbonell L, Valenzuela-Silva CM, Tuero-Iglesias AD, Moreira-Martínez M, Marrero-Rodríguez I, López-Mola E, López-Saura PA.

BMC Pharmacol Toxicol. 2013 Sep 3;14:44. doi: 10.1186/2050-6511-14-44.

4.

Granulation response and partial wound closure predict healing in clinical trials on advanced diabetes foot ulcers treated with recombinant human epidermal growth factor.

Valenzuela-Silva CM, Tuero-Iglesias ÁD, García-Iglesias E, González-Díaz O, Del Río-Martín A, Yera Alos IB, Fernández-Montequín JI, López-Saura PA.

Diabetes Care. 2013 Feb;36(2):210-5. doi: 10.2337/dc12-1323. Epub 2012 Sep 10.

5.

CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research.

Perea SE, Baladron I, Garcia Y, Perera Y, Lopez A, Soriano JL, Batista N, Palau A, Hernández I, Farina H, Garcia I, Gonzalez L, Gil J, Rodriguez A, Solares M, Santana A, Cruz M, Lopez M, Valenzuela C, Reyes O, López-Saura PA, González CA, Diaz A, Castellanos L, Sanchez A, Betancourt L, Besada V, González LJ, Garay H, Gómez R, Gómez DE, Alonso DF, Perrin P, Renualt JY, Sigman H, Herrera L, Acevedo B.

Mol Cell Biochem. 2011 Oct;356(1-2):45-50. doi: 10.1007/s11010-011-0950-y. Epub 2011 Jul 7.

PMID:
21735096
6.

C-Phycocyanin is neuroprotective against global cerebral ischemia/reperfusion injury in gerbils.

Pentón-Rol G, Marín-Prida J, Pardo-Andreu G, Martínez-Sánchez G, Acosta-Medina EF, Valdivia-Acosta A, Lagumersindez-Denis N, Rodríguez-Jiménez E, Llópiz-Arzuaga A, López-Saura PA, Guillén-Nieto G, Pentón-Arias E.

Brain Res Bull. 2011 Aug 10;86(1-2):42-52. doi: 10.1016/j.brainresbull.2011.05.016. Epub 2011 Jun 6.

PMID:
21669260
7.

Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.

García-García I, González-Delgado CA, Valenzuela-Silva CM, Díaz-Machado A, Cruz-Díaz M, Nodarse-Cuní H, Pérez-Pérez O, Bermúdez-Badell CH, Ferrero-Bibilonia J, Páez-Meireles R, Bello-Rivero I, Castro-Odio FR, López-Saura PA; FarmaPEG Study Group.

BMC Pharmacol. 2010 Nov 23;10:15. doi: 10.1186/1471-2210-10-15.

8.

C-Phycocyanin ameliorates experimental autoimmune encephalomyelitis and induces regulatory T cells.

Pentón-Rol G, Martínez-Sánchez G, Cervantes-Llanos M, Lagumersindez-Denis N, Acosta-Medina EF, Falcón-Cama V, Alonso-Ramírez R, Valenzuela-Silva C, Rodríguez-Jiménez E, Llópiz-Arzuaga A, Marín-Prida J, López-Saura PA, Guillén-Nieto GE, Pentón-Arias E.

Int Immunopharmacol. 2011 Jan;11(1):29-38. doi: 10.1016/j.intimp.2010.10.001. Epub 2010 Oct 23.

PMID:
20971186
9.

Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study.

Fernández-Montequín JI, Valenzuela-Silva CM, Díaz OG, Savigne W, Sancho-Soutelo N, Rivero-Fernández F, Sánchez-Penton P, Morejón-Vega L, Artaza-Sanz H, García-Herrera A, González-Benavides C, Hernández-Cañete CM, Vázquez-Proenza A, Berlanga-Acosta J, López-Saura PA; Cuban Diabetic Foot Study Group.

Int Wound J. 2009 Dec;6(6):432-43. doi: 10.1111/j.1742-481X.2009.00641.x.

PMID:
20051095
10.

TNF-alpha and IL-10 downregulation and marked oxidative stress in Neuromyelitis Optica.

Pentón-Rol G, Cervantes-Llanos M, Martínez-Sánchez G, Cabrera-Gómez JA, Valenzuela-Silva CM, Ramírez-Nuñez O, Casanova-Orta M, Robinson-Agramonte MA, Lopategui-Cabezas I, López-Saura PA.

J Inflamm (Lond). 2009 Jun 2;6:18. doi: 10.1186/1476-9255-6-18.

11.

CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo.

Perea SE, Reyes O, Baladron I, Perera Y, Farina H, Gil J, Rodriguez A, Bacardi D, Marcelo JL, Cosme K, Cruz M, Valenzuela C, López-Saura PA, Puchades Y, Serrano JM, Mendoza O, Castellanos L, Sanchez A, Betancourt L, Besada V, Silva R, López E, Falcón V, Hernández I, Solares M, Santana A, Díaz A, Ramos T, López C, Ariosa J, González LJ, Garay H, Gómez D, Gómez R, Alonso DF, Sigman H, Herrera L, Acevedo B.

Mol Cell Biochem. 2008 Sep;316(1-2):163-7. doi: 10.1007/s11010-008-9814-5. Epub 2008 Jun 25.

PMID:
18575815
12.

Adjuvant interferon gamma in patients with pulmonary atypical Mycobacteriosis: a randomized, double-blind, placebo-controlled study.

Milanés-Virelles MT, García-García I, Santos-Herrera Y, Valdés-Quintana M, Valenzuela-Silva CM, Jiménez-Madrigal G, Ramos-Gómez TI, Bello-Rivero I, Fernández-Olivera N, Sánchez-de la Osa RB, Rodríguez-Acosta C, González-Méndez L, Martínez-Sánchez G, López-Saura PA; MACGAM Study Group.

BMC Infect Dis. 2008 Feb 11;8:17. doi: 10.1186/1471-2334-8-17.

13.

Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation.

Fernández-Montequín JI, Infante-Cristiá E, Valenzuela-Silva C, Franco-Pérez N, Savigne-Gutierrez W, Artaza-Sanz H, Morejón-Vega L, González-Benavides C, Eliseo-Musenden O, García-Iglesias E, Berlanga-Acosta J, Silva-Rodríguez R, Betancourt BY, López-Saura PA; Cuban Citoprot-P Study Group.

Int Wound J. 2007 Dec;4(4):333-43. Epub 2007 Oct 22.

PMID:
17953679
14.

Pharmacovigilance program to monitor adverse reactions of recombinant streptokinase in acute myocardial infarction.

Betancourt BY, Marrero-Miragaya MA, Jiménez-López G, Valenzuela-Silva C, García-Iglesias E, Hernández-Bernal F, Debesa-García F, González-López T, Alvarez-Falcón L, López-Saura PA; Cuban National Network of Pharmacoepidemiology.

BMC Clin Pharmacol. 2005 Nov 2;5:5.

15.

Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.

Pérez-Oliva JF, Casanova-González M, García-García I, Porrero-Martín PJ, Valenzuela-Silva CM, Hernández-Montero T, Lagarde-Ampudia M, Casanova-Kutsareva Y, Avila-Albuerne Y, Vargas-Batista A, Bobillo-López H, Herrera-Valdés R, López-Saura PA; Bioequivalence Study of Erythropoietin Group.

BMC Nephrol. 2005 May 23;6:5.

16.

Adjuvant interferon gamma in patients with drug - resistant pulmonary tuberculosis: a pilot study.

Suárez-Méndez R, García-García I, Fernández-Olivera N, Valdés-Quintana M, Milanés-Virelles MT, Carbonell D, Machado-Molina D, Valenzuela-Silva CM, López-Saura PA.

BMC Infect Dis. 2004 Oct 22;4:44.

17.

Thrombolysis with recombinant streptokinase in Cuba.

Lopez-Saura PA.

BMJ. 2003 Feb 22;326(7386):448. No abstract available.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk